67N0.F GENOR BIOPHARMA DL-00002

Healthcare Biotechnology Frankfurt Exchange
0.1823 EUR
Close of Nov 11, 2026
0.1520 0.4100
Market cap
EUR 95.7M
P/E
17.1x
P/B
1.32x
ROE
-4.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2024.

Is 67N0.F undervalued?

Graham number
Price0.1823
Graham value0.1818
Premium0.3%

67N0.F trades 0.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GENOR BIOPHARMA DL-00002 fundamental analysis

No fundamental analysis for GENOR BIOPHARMA DL-00002 yet.

GENOR BIOPHARMA DL-00002 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GENOR BIOPHARMA DL-00002

Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in Phase III clinical trial for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidat…

Full company profile